Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221


Screening for cryptococcal antigenemia in anti-retroviral naïve AIDS patients in benin city, Nigeria.

Osazuwa F, Dirisu JO, Okuonghae PE, Ugbebor O.

Oman Med J. 2012 May;27(3):228-31. doi: 10.5001/omj.2012.51.


Comparison of cryptococcal antigenemia between antiretroviral naïve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia.

Beyene T, Woldeamanuel Y, Asrat D, Ayana G, Boulware DR.

PLoS One. 2013 Oct 4;8(10):e75585. doi: 10.1371/journal.pone.0075585. eCollection 2013.


Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.

Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, Weidle PJ, Downing R, Coutinho A, Mermin J.

Trop Med Int Health. 2007 Aug;12(8):929-35.


Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.

McKenney J, Bauman S, Neary B, Detels R, French A, Margolick J, Doherty B, Klausner JD.

Clin Infect Dis. 2015 Mar 15;60(6):959-65. doi: 10.1093/cid/ciu937. Epub 2014 Nov 24.


Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.

Rugemalila J, Maro VP, Kapanda G, Ndaro AJ, Jarvis JN.

Trop Med Int Health. 2013 Sep;18(9):1075-1079. doi: 10.1111/tmi.12157.


Cryptococcal disease in patients with or without human immunodeficiency virus: clinical presentation and monitoring of serum cryptococcal antigen titers.

Lin TY, Yeh KM, Lin JC, Wang NC, Peng MY, Chang FY.

J Microbiol Immunol Infect. 2009 Jun;42(3):220-6.


The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts.

Pongsai P, Atamasirikul K, Sungkanuparph S.

J Infect. 2010 Jun;60(6):474-7. doi: 10.1016/j.jinf.2010.03.015. Epub 2010 Mar 27.


Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.

Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, Kamya MR, Bohjanen PR, Boulware DR.

Clin Infect Dis. 2010 Aug 15;51(4):448-55. doi: 10.1086/655143.


Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients.

Micol R, Lortholary O, Sar B, Laureillard D, Ngeth C, Dousset JP, Chanroeun H, Ferradini L, Guerin PJ, Dromer F, Fontanet A.

J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):555-9.


Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.

Vidal JE, Toniolo C, Paulino A, Colombo A, Dos Anjos Martins M, da Silva Meira C, Pereira-Chioccola VL, Figueiredo-Mello C, Barros T, Duarte J, Fonseca F, Alves Cunha M, Mendes C, Ribero T, Dos Santos Lazera M, Rajasingham R, Boulware DR.

Trop Med Int Health. 2016 Dec;21(12):1539-1544. doi: 10.1111/tmi.12790. Epub 2016 Oct 24.


High prevalence of cryptococcal infection among HIV-infected patients hospitalized with pneumonia in Thailand.

Harris JR, Lindsley MD, Henchaichon S, Poonwan N, Naorat S, Prapasiri P, Chantra S, Ruamcharoen F, Chang LS, Chittaganpitch M, Mehta N, Peruski L, Maloney SA, Park BJ, Baggett HC.

Clin Infect Dis. 2012 Mar 1;54(5):e43-50. doi: 10.1093/cid/cir903. Epub 2011 Dec 23.


Screening for cryptococcal antigenemia using the lateral flow assay in antiretroviral therapy-naïve HIV-positive adults at an Ethiopian hospital clinic.

Reepalu A, Balcha TT, Yitbarek T, Jarso G, Sturegård E, Björkman P.

BMC Res Notes. 2015 Nov 23;8:702. doi: 10.1186/s13104-015-1707-6.


Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam.

Smith RM, Nguyen TA, Ha HT, Thang PH, Thuy C, Lien TX, Bui HT, Le TH, Struminger B, McConnell MS, Fanfair RN, Park BJ, Harris JR.

PLoS One. 2013 Apr 23;8(4):e62213. doi: 10.1371/journal.pone.0062213. Print 2013.


Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in Uganda.

Andama AO, den Boon S, Meya D, Cattamanchi A, Worodria W, Davis JL, Walter ND, Yoo SD, Kalema N, Haller B, Huang L; International HIV-Associated Opportunistic Pneumonias (IHOP) Study.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):189-94. doi: 10.1097/QAI.0b013e3182926f95.


Brief Report: Geographical Variation in Prevalence of Cryptococcal Antigenemia Among HIV-Infected, Treatment-Naive Patients in Nigeria: A Multicenter Cross-Sectional Study.

Ezeanolue EE, Nwizu C, Greene GS, Amusu O, Chukwuka C, Ndembi N, Smith RM, Chiller T, Pharr J, Kozel TR.

J Acquir Immune Defic Syndr. 2016 Sep 1;73(1):117-21. doi: 10.1097/QAI.0000000000001048.


Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa.

Govender NP, Roy M, Mendes JF, Zulu TG, Chiller TM, Karstaedt AS.

HIV Med. 2015 Sep;16(8):468-76. doi: 10.1111/hiv.12245. Epub 2015 Feb 17.


Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study.

Longley N, Jarvis JN, Meintjes G, Boulle A, Cross A, Kelly N, Govender NP, Bekker LG, Wood R, Harrison TS.

Clin Infect Dis. 2016 Mar 1;62(5):581-587. doi: 10.1093/cid/civ936. Epub 2015 Nov 12.


Profile of central nervous system disease in HIV/AIDS patients with special reference to cryptococcal infections.

Wadhwa A, Kaur R, Bhalla P.

Neurologist. 2008 Jul;14(4):247-51. doi: 10.1097/NRL.0b013e3181678a7a.


Supplemental Content

Support Center